Duchenne muscular dystrophy (DMD) is the most severe form of muscular dystrophy which
leads to progressive muscle degeneration and inflammation. The receptor activator of …

Bisphosphonates prevent bone loss in glucocorticoid (GC)-treated boys with Duchenne
muscular dystrophy (DMD) and are recommended as standard of care. Targeting receptor …

Although there is a strong association between osteoporosis and skeletal muscle
atrophy/dysfunction, the functional relevance of a particular biological pathway that …

Receptor activator of NF-κB ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits,
osteoclastogenesis. A neutralizing Ab against RANKL, denosumab, improves bone strength …

Receptor activator of NF-κB ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits,
osteoclastogenesis. A neutralizing Ab against RANKL, denosumab, improves bone strength …

Duchenne muscular dystrophy (DMD) is a lethal X-linked disorder associated with
dystrophin deficiency that results in chronic inflammation and severe skeletal muscle …

Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease due to a
mutation in the dystrophin gene and the consequential protein deficiency in muscle. How the …

Duchenne muscular dystrophy (DMD) is an X-linked, degenerative muscle disease that is
exacerbated by secondary inflammation. Here, we characterized the immunological milieu …

Bone and muscle are tightly coupled and form a functional unit under normal conditions. The
receptor-activator of nuclear factor κB/receptor-activator of nuclear factor κB …

Abstract Purpose of Review In Duchenne muscular dystrophy (DMD), the progressive
skeletal and cardiac muscle dysfunction and degeneration is accompanied by low bone …